Extensive mutagenesis experiments corroborate a structural model for the DNA deaminase domain of APOBEC3G

FEBS Letters

Volumn 581, Issue 24, 2007, Pages 4761-4766

  Chen, Kuan Ming ^a,b   Martemyanova, Natalia ^a,b,c   Lu, Yongjian ^a,b   Shindo, Keisuke ^a,b,c   Matsuo, Hiroshi ^a,b   Harris, Reuben S ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Minnesota Medical School Minneapolis   (United States)

Author keywords

APOBEC3G; DNA cytosine deamination; DNA editing; Hypermutation

Indexed keywords

ALANINE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; DEAMINASE; DNA; MONOMER; PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; DEAMINATION; ENZYME ACTIVE SITE; GEL PERMEATION CHROMATOGRAPHY; GENE DELETION; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN STRUCTURE; STRUCTURAL GENE;

AMINO ACID MOTIFS; CHROMATOGRAPHY, GEL; CYTIDINE DEAMINASE; DEAMINATION; DNA; GENE EXPRESSION; HUMANS; MODELS, MOLECULAR; MUTAGENESIS; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 34548697547     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.08.076     Document Type: Article

References (21)

1. Cullen B.R. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol. 80 (2006) 1067-1076
2. Longerich S., Basu U., Alt F., and Storb U. AID in somatic hypermutation and class switch recombination. Curr. Opin. Immunol. 18 (2006) 164-174
3. Sheehy A.M., Gaddis N.C., Choi J.D., and Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 (2002) 646-650
4. Harris R.S., Petersen-Mahrt S.K., and Neuberger M.S. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 10 (2002) 1247-1253
5. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., and Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 113 (2003) 803-809
6. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., and Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424 (2003) 99-103
7. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., and Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424 (2003) 94-98
8. Chelico L., Pham P., Calabrese P., and Goodman M.F. APOBEC3G DNA deaminase acts processively 3′ → 5′ on single-stranded DNA. Nat. Struct. Mol. Biol. 13 (2006) 392-399
9. Haché G., Liddament M.T., and Harris R.S. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280 (2005) 10920-10924
10. Iwatani Y., Takeuchi H., Strebel K., and Levin J.G. Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 80 (2006) 5992-6002
11. Newman E.N., Holmes R.K., Craig H.M., Klein K.C., Lingappa J.R., Malim M.H., and Sheehy A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15 (2005) 166-170
12. Navarro F., Bollman B., Chen H., Konig R., Yu Q., Chiles K., and Landau N.R. Complementary function of the two catalytic domains of APOBEC3G. Virology 333 (2005) 374-386
13. Janini M., Rogers M., Birx D.R., and McCutchan F.E. Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J. Virol. 75 (2001) 7973-7986
14. Combet C., Blanchet C., Geourjon C., and Deleage G. NPS@: network protein sequence analysis. Trends Biochem. Sci. 25 (2000) 147-150
15. Guermeur Y., Geourjon C., Gallinari P., and Deleage G. Improved performance in protein secondary structure prediction by inhomogeneous score combination. Bioinformatics 15 (1999) 413-421
16. Prochnow C., Bransteitter R., Klein M.G., Goodman M.F., and Chen X.S. The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 445 (2007) 447-451
17. Li J., Potash M.J., and Volsky D.J. Functional domains of APOBEC3G required for antiviral activity. J. Cell Biochem. 92 (2004) 560-572
18. Shindo K., Takaori-Kondo A., Kobayashi M., Abudu A., Fukunaga K., and Uchiyama T. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 278 (2003) 44412-44416
19. Opi S., et al. Monomeric APOBEC3G is catalytically active and has antiviral activity. J. Virol. 80 (2006) 4673-4682
20. Jonsson S.R., Hache G., Stenglein M.D., Fahrenkrug S.C., Andresdottir V., and Harris R.S. Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res. 34 (2006) 5683-5694
21. Zhang K.L., Mangeat B., Ortiz M., Zoete V., Trono D., Telenti A., and Michielin O. Model structure of human APOBEC3G. PLoS ONE 2 (2007) e378